Febuxostat Krka 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0009 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
16/02/2024 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
R/0008 
Renewal of the marketing authorisation. 
12/10/2023 
07/12/2023 
SmPC and 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
Labelling 
Febuxostat Krka in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IB/0007 
C.I.2.a - Change in the SPC, Labelling or PL of a 
11/05/2023 
07/12/2023 
SmPC 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0006/G 
This was an application for a group of variations. 
04/04/2022 
31/03/2023 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
N/0005 
Minor change in labelling or package leaflet not 
07/12/2021 
31/03/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0004 
B.II.b.3.z - Change in the manufacturing process of 
28/08/2020 
n/a 
the finished or intermediate product - Other variation 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0003 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/10/2019 
30/09/2020 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IB/0002/G 
This was an application for a group of variations. 
19/08/2019 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.c.1.a - Change in immediate packaging of the AS 
- Qualitative and/or quantitative composition 
IB/0001/G 
This was an application for a group of variations. 
05/07/2019 
n/a 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
Page 3/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
